Figure legends
Figure 1: Schematic pregnancy PBPK model diagram illustrating organs and
tissues as compartments, and blood flows as (blue/red) arrows. IM –
intramuscular.
Figure 2. Predicted average plasma concentration-time profile of
approved dosing regimens of LAI cabotegravir LAI rilpivirine without
oral lead-in in pregnant and non-pregnant adults. A – Monthly LAI
cabotegravir; B - Bimonthly LAI cabotegravir; C - Monthly LAI
rilpivirine; and D - Bimonthly LAI rilpivirine. Ctrough– plasma concentration at the end of the dosing interval.
Figure S1: Sensitivity analyses of plasma concentrations of (A)
rilpivirine and (B) cabotegravir to variations (± 37.5 and 75%) of
their respective release rates from the long-acting injectable
formulations in the PBPK model. The sensitivity analysis was performed
for single doses of 900 mg long-acting rilpivirine and 600 mg
long-acting cabotegravir.